AAAAAA
Results: 1-25/26
Authors:
BRAUN TC
HAGEN N
BROWN P
Citation: Tc. Braun et al., REGIONAL-PLANNING - COORDINATING PALLIATIVE CARE BETWEEN A REGIONAL CANCER CLINIC, A REGIONAL PALLIATIVE CARE SERVICE, AND COMMUNITY FAMILYPHYSICIANS, Journal of palliative care, 14(3), 1998, pp. 107-108
Authors:
BRAUN TC
HAGEN N
HATFIELD R
WYSE G
Citation: Tc. Braun et al., CARDIAC-PACEMAKERS IN TERMINAL CARE, Journal of palliative care, 14(3), 1998, pp. 117-117
Authors:
MOLIN DE
HAHN A
HAGEN N
FEASBY TE
Citation: De. Molin et al., PAIN AND OPIOID ANALGESICS IN GUILLAIN-BARRE-SYNDROME - REPLY, Neurology, 51(3), 1998, pp. 924-924
Authors:
HAGEN N
SWANSON R
Citation: N. Hagen et R. Swanson, STRYCHNINE-LIKE MULTIFOCAL MYOCLONUS AND SEIZURES IN EXTREMELY HIGH-DOSE OPIOID ADMINISTRATION - TREATMENT STRATEGIES, Journal of pain and symptom management, 14(1), 1997, pp. 51-58
Authors:
ERNST DS
BRASHER P
HAGEN N
PATERSON AHG
MACDONALD RN
BRUERA E
Citation: Ds. Ernst et al., A RANDOMIZED, CONTROLLED TRIAL OF INTRAVENOUS CLODRONATE IN PATIENTS WITH METASTATIC BONE-DISEASE AND PAIN, Journal of pain and symptom management, 13(6), 1997, pp. 319-326
Authors:
SCOTT JN
REWCASTLE NB
BRASHER P
MACKINNON J
HAGEN N
FORSYTH P
CAIRNCROSS JG
FULTON D
Citation: Jn. Scott et al., LONG-TERM GLIOBLASTOMA-MULTIFORME SURVIVORS - A POPULATION-BASED STUDY IN ALBERTA FROM 1975 TO 1991, Annals of neurology, 42(3), 1997, pp. 279-279
Authors:
MOULIN DE
HAHN A
HAGEN N
FEASBY TE
Citation: De. Moulin et al., PAIN IN GUILLAIN-BARRE-SYNDROME - REPLY, Neurology, 49(5), 1997, pp. 1474-1474
Authors:
MOULIN DE
HAGEN N
FEASBY TE
AMIREH R
HAHN A
Citation: De. Moulin et al., PAIN IN GUILLAIN-BARRE-SYNDROME, Neurology, 48(2), 1997, pp. 328-331
Authors:
HAMILTON MG
LAURYSSEN C
HAGEN N
Citation: Mg. Hamilton et al., FOCAL MIDBRAIN GLIOMA - LONG-TERM SURVIVAL IN A COHORT (VOL 23, PG 206, 1996), Canadian journal of neurological sciences, 23(4), 1996, pp. 317-317
Authors:
HAMILTON MG
LAURYSSEN C
HAGEN N
Citation: Mg. Hamilton et al., FOCAL MIDBRAIN GLIOMA - LONG-TERM SURVIVAL IN A COHORT OF 16 PATIENTSAND THE IMPLICATIONS FOR MANAGEMENT, Canadian journal of neurological sciences, 23(3), 1996, pp. 204-207
Authors:
SCOTT J
REWCASTLE NB
BRASHER P
MACKINNON J
HAGEN N
CAIRNCROSS JG
FORSYTH P
Citation: J. Scott et al., WHICH GBM PATIENT WILL BE A LONG-TERM SURVIVOR - A CASE-CONTROLLED, POPULATION-BASED STUDY IN SOUTHERN ALBERTA, Neurology, 46(2), 1996, pp. 2040-2040
Authors:
BABUL N
DARKE AC
HAGEN N
Citation: N. Babul et al., HYDROMORPHONE METABOLITE ACCUMULATION IN RENAL-FAILURE, Journal of pain and symptom management, 10(3), 1995, pp. 184-186
Authors:
HAGEN N
YOUNG J
MACDONALD N
Citation: N. Hagen et al., PAIN MANAGEMENT NOW PART OF STANDARDS FOR CARE IN CANCER CENTERS - RESPONSE, CMAJ. Canadian Medical Association journal, 153(6), 1995, pp. 742-742
Authors:
HAGEN N
YOUNG J
MACDONALD N
Citation: N. Hagen et al., DIFFUSION OF STANDARDS OF CARE FOR CANCER PAIN, CMAJ. Canadian Medical Association journal, 152(8), 1995, pp. 1205-1209
Authors:
HAGEN N
THIRLWELL MP
DHALIWAL HS
BABUL N
HARSANYI Z
DARKE AC
Citation: N. Hagen et al., STEADY-STATE PHARMACOKINETICS OF HYDROMORPHONE AND HYDROMORPHONE-3-GLUCURONIDE IN CANCER-PATIENTS AFTER IMMEDIATE AND CONTROLLED-RELEASE HYDROMORPHONE, Journal of clinical pharmacology, 35(1), 1995, pp. 37-44
Authors:
MECKLING S
FORSYTH P
BRASHER P
DOLD O
HAGEN N
Citation: S. Meckling et al., MALIGNANT SUPRATENTORIAL GLIOMA (MSG) IN THE ELDERLY - IS RADIOTHERAPY (RT) USEFUL, Neurology, 45(4), 1995, pp. 262-262
Authors:
WEAVER S
FORSYTH P
FULTON D
BRASHER P
HAGEN N
SUTHERLAND G
DEANGELIS L
Citation: S. Weaver et al., A PROSPECTIVE RANDOMIZED STUDY OF PROPHYLACTIC ANTICONVULSANTS (AC) IN PATIENTS WITH PRIMARY BRAIN-TUMORS (PBT) OR METASTATIC BRAIN-TUMORS (MBT) AND WITHOUT PRIOR SEIZURES (SZ) - A PRELIMINARY-ANALYSIS OF 67 PATIENTS, Neurology, 45(4), 1995, pp. 263-263
Authors:
MOULIN DE
HAGEN N
FEASBY TE
AMIREH R
HAHN AF
Citation: De. Moulin et al., PAIN IN GUILLAIN-BARRE-SYNDROME (GBS), Neurology, 45(4), 1995, pp. 395-395
Authors:
BABUL N
HAGEN N
THIRLWELL M
DHALIWAL H
HARSANYI Z
DARKE A
Citation: N. Babul et al., STEADY-STATE DISPOSITION OF HYDROMORPHONE AND HYDROMORPHONE-3-GLUCURONIDE IN CANCER-PATIENTS, Clinical pharmacology and therapeutics, 57(2), 1995, pp. 165-165
Authors:
HAGEN N
FLYNNE P
HAYS H
MACDONALD N
Citation: N. Hagen et al., GUIDELINES FOR MANAGING CHRONIC NONMALIGNANT PAIN, Canadian family physician, 41, 1995, pp. 49-53
Authors:
HAGEN N
FLYNNE P
HAYS H
MACDONALD N
Citation: N. Hagen et al., SPECIFICS NEEDED ON SAFE DOSAGE - RESPONSE, Canadian family physician, 41, 1995, pp. 372-373
Authors:
HAGEN N
FLYNNE P
HAYS H
MACDONALD N
Citation: N. Hagen et al., BEWARE OF INCORRECT LABELING - RESPONSE, Canadian family physician, 41, 1995, pp. 562-562
Authors:
MACDONALD SM
HAGEN N
BRUERA E
Citation: Sm. Macdonald et al., PROXIMAL MUSCLE WEAKNESS IN A PATIENT WITH HEPATOCELLULAR-CARCINOMA, Journal of pain and symptom management, 9(5), 1994, pp. 346-350
Authors:
HAGEN N
TEMPLE WJ
BAKER T
Citation: N. Hagen et al., COUGH AS A SYSTEMIC MANIFESTATION OF CANCER, Journal of pain and symptom management, 9(1), 1994, pp. 3-4
Authors:
HAYS H
HAGEN N
THIRLWELL M
DHALIWAL H
BABUL N
HARSANYI Z
DARKE AC
Citation: H. Hays et al., COMPARATIVE CLINICAL EFFICACY AND SAFETY OF IMMEDIATE-RELEASE AND CONTROLLED-RELEASE HYDROMORPHONE FOR CHRONIC SEVERE CANCER PAIN, Cancer, 74(6), 1994, pp. 1808-1816